Francesca Zacchi

🧬 Can combining targeted therapies improve prostate cancer outcomes—or are we adding toxicity without enough clinical benefit? nature.com/articles/s41591-0… Talazoparib plus enzalutamide in high-volume metastatic hormone-naive prostate cancer: a randomized phase 2 trial A randomized phase 2 trial evaluated talazoparib plus enzalutamide 🆚 enzalutamide 💊 alone in high-volume metastatic hormone-naive #ProstateCancer ➡️ Although combination therapy achieved a 73% PSA response rate at 12 months, superiority over monotherapy was not established. ➡️ Grade ≥3 adverse events were more frequent with combination treatment, including two fatal myeloid neoplasms. ✅ Tumor analyses revealed androgen receptor inhibition altered gene expression without impairing functional homologous recombination, highlighting challenges in identifying patients most likely to benefit. @FrancescaZacc14, @Ecastromarcos, @AlejoRodrguezV1, @begona_mellado, @cdanicas, @BorqueFernando, @Jacquesplanas, @Dav_Lorente, @julianbrandariz, @_NicoAnse, @AnaVivancosVHIO, @PaoloNuciforo, @eportacangen, @quimmateo @OncoAlert 🚨 #LPCCC27 @Silke_Gillessen @AOmlin @ProfKHerrmann @weoncologists